Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Borchmann

Showing results (101-110 of 252) with videos related to

Pageof 26
Sort By:
British Journal of Haematology|January 24, 2021
Non-Hodgkin lymphoma after treatment for classical Hodgkin lymphoma: a report from the German Hodgkin Study GroupDennis A Eichenauer, Horst Müller, Leonard Elger, et al.
Blood|September 1, 2018
Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphomaCarsten Kobe, Helen Goergen, Christian Baues, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2017
Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 TrialsStephanie Sasse, Paul J Bröckelmann, Helen Goergen, et al.
Blood|June 17, 2010
Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)Teresa V Halbsguth, Lucia Nogová, Horst Mueller, et al.
Leukemia & Lymphoma|October 22, 2013
Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplantBastian von Tresckow, Horst Müller, Dennis A Eichenauer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 9, 2018
Metabolic Tumour Volume for Response Prediction in Advanced-Stage Hodgkin LymphomaJasmin Mettler, Horst Müller, Conrad-Amadeus Voltin, et al.
European Journal of Haematology|March 22, 2005
Imaging of central nervous system lymphomas with iodine-123 labeled rituximabMarkus Dietlein, Hendrik Pels, Holger Schulz, et al.
Haematologica|August 26, 2003
Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomasPeter Borchmann, Franck Morschhauser, Anne Parry, et al.
Leukemia|May 13, 2025
Refining histopathological growth pattern-based risk group discrimination in nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study GroupDennis A Eichenauer, Aylin Basaran, Ina Bühnen, et al.
British Journal of Haematology|June 20, 2020
How I treat advanced Hodgkin lymphoma - a global viewPeter Hokland, Mansi Shah, Kevin David, et al.
Pageof 26

Showing results (101-110 of 252) with videos related to

Sort By:
Pageof 26
British Journal of Haematology|January 24, 2021
Non-Hodgkin lymphoma after treatment for classical Hodgkin lymphoma: a report from the German Hodgkin Study GroupDennis A Eichenauer, Horst Müller, Leonard Elger, et al.
Blood|September 1, 2018
Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphomaCarsten Kobe, Helen Goergen, Christian Baues, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2017
Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 TrialsStephanie Sasse, Paul J Bröckelmann, Helen Goergen, et al.
Blood|June 17, 2010
Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)Teresa V Halbsguth, Lucia Nogová, Horst Mueller, et al.
Leukemia & Lymphoma|October 22, 2013
Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplantBastian von Tresckow, Horst Müller, Dennis A Eichenauer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 9, 2018
Metabolic Tumour Volume for Response Prediction in Advanced-Stage Hodgkin LymphomaJasmin Mettler, Horst Müller, Conrad-Amadeus Voltin, et al.
European Journal of Haematology|March 22, 2005
Imaging of central nervous system lymphomas with iodine-123 labeled rituximabMarkus Dietlein, Hendrik Pels, Holger Schulz, et al.
Haematologica|August 26, 2003
Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomasPeter Borchmann, Franck Morschhauser, Anne Parry, et al.
Leukemia|May 13, 2025
Refining histopathological growth pattern-based risk group discrimination in nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study GroupDennis A Eichenauer, Aylin Basaran, Ina Bühnen, et al.
British Journal of Haematology|June 20, 2020
How I treat advanced Hodgkin lymphoma - a global viewPeter Hokland, Mansi Shah, Kevin David, et al.
Pageof 26